MustGrow Biologics(MGROF)
$0.300.00 (0.00%)
MGROF
MustGrow Biologics financials statements
$0.30
At close:0.00 (0.00%)
MustGrow Biologics (MGROF) Ratios
13 Followers
MustGrow Biologics Ratios
MGROF's free cash flow for Q2 2026 was C$613.26K. For the 2026 fiscal year, MGROF's free cash flow was decreased by C$-4.00 and operating cash flow was C$613.26K. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.48 | 1.61 | 5.72 | 4.63 | 11.24 |
| Quick Ratio | 0.51 | 1.12 | 5.72 | 4.63 | 11.24 |
| Cash Ratio | 0.44 | 1.03 | 5.62 | 4.56 | 11.15 |
| Solvency Ratio | -3.24 | -1.51 | -0.50 | -2.94 | -2.46 |
| Operating Cash Flow Ratio | -2.44 | -1.24 | -0.24 | -2.11 | -2.79 |
| Short-Term Operating Cash Flow Coverage | -11.69 | -9.09 | -0.48 | -8.06 | -6.57 |
| Net Current Asset Value | C$ 834.49K | C$ 1.41M | C$ 5.58M | C$ 5.24M | C$ 8.46M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 0.10 | 0.11 | 0.11 | 0.08 |
| Debt-to-Equity Ratio | 0.67 | 0.24 | 0.14 | 0.14 | 0.09 |
| Debt-to-Capital Ratio | 0.40 | 0.19 | 0.12 | 0.13 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.13 | 0.05 | 0.02 | 0.06 | 0.04 |
| Financial Leverage Ratio | 3.57 | 2.50 | 1.24 | 1.36 | 1.15 |
| Debt Service Coverage Ratio | -8.31 | -12.42 | -1.09 | -13.41 | -7.17 |
| Interest Coverage Ratio | -19.97 | 0.00 | 0.00 | -551.93 | -57.07 |
| Debt to Market Cap | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 |
| Net Debt to EBITDA | 0.05 | 0.51 | 8.95 | 1.13 | 2.95 |
| Profitability Margins | |||||
| Gross Profit Margin | 17.03% | 75.56% | 91.84% | 100.00% | 100.00% |
| EBIT Margin | -75.45% | -1228.27% | -14.37% | -85750.50% | -23398.17% |
| EBITDA Margin | -74.84% | -1228.27% | -14.37% | -85750.50% | -23398.17% |
| Operating Profit Margin | -75.45% | -1284.91% | -17.08% | -85750.50% | -23398.17% |
| Pretax Profit Margin | -87.58% | -1228.27% | -14.37% | -85905.87% | -23808.18% |
| Net Profit Margin | -87.58% | -1228.27% | -14.37% | -85905.87% | -23808.18% |
| Continuous Operations Profit Margin | -87.58% | -1228.27% | -14.37% | -85905.87% | -23808.18% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 116.07% | 95.59% | 84.09% | 100.18% | 101.75% |
| Return on Assets (ROA) | -234.64% | -90.26% | -9.76% | -78.01% | -31.58% |
| Return on Equity (ROE) | -837.00% | -225.33% | -12.12% | -106.24% | -36.23% |
| Return on Capital Employed (ROCE) | -613.93% | -202.97% | -14.06% | -99.31% | -34.07% |
| Return on Invested Capital (ROIC) | -430.85% | -175.56% | -12.69% | -92.62% | -32.71% |
| Return on Tangible Assets | -234.64% | -100.99% | -9.76% | -78.01% | -31.58% |
| Earnings Yield | -21.19% | -8.24% | -1.05% | -3.21% | -1.97% |
| Efficiency Ratios | |||||
| Receivables Turnover | 119.61 | 3.87 | 49.70 | 0.07 | 0.20 |
| Payables Turnover | 4.19 | 0.04 | 1.20 | 0.00 | 0.00 |
| Inventory Turnover | 3.44 | 0.07 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 254.09 | 2.21 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 2.68 | 0.07 | 0.68 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 6.03 | 0.11 | 0.83 | 0.00 | 0.00 |
| Cash Conversion Cycle | 22.01 | -3932.02 | -297.94 | 4945.61 | 1823.61 |
| Days of Sales Outstanding | 3.05 | 94.25 | 7.34 | 4945.61 | 1823.61 |
| Days of Inventory Outstanding | 106.13 | 5367.21 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 87.17 | 9393.48 | 305.29 | 0.00 | 0.00 |
| Operating Cycle | 109.18 | 5461.46 | 7.34 | 4945.61 | 1823.61 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.09 | -0.07 | -0.01 | -0.07 | -0.06 |
| Free Cash Flow Per Share | -0.12 | -0.07 | -0.01 | -0.07 | -0.06 |
| Dividend Paid and CapEx Coverage Ratio | -3.37 | -894574.00 | -73691.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -3.37 | -894574.00 | -73691.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -8.66 | -6.91 | -0.39 | -4.29 | -3.22 |
| Operating Cash Flow to Sales Ratio | -0.61 | -8.99 | -0.06 | -502.78 | -187.41 |
| Free Cash Flow Yield | -19.15% | -6.03% | -0.46% | -1.88% | -1.55% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.85 | -12.14 | -95.08 | -31.17 | -50.82 |
| Price-to-Sales (P/S) Ratio | 4.13 | 149.08 | 13.66 | 26778.26 | 12098.91 |
| Price-to-Book (P/B) Ratio | 39.49 | 27.35 | 11.53 | 33.12 | 18.41 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.22 | -16.58 | -218.36 | -53.26 | -64.56 |
| Price-to-Operating Cash Flow Ratio | -6.77 | -16.58 | -218.36 | -53.26 | -64.56 |
| Price-to-Earnings Growth (PEG) Ratio | -0.13 | -0.02 | 1.08 | -0.55 | 2.30 |
| Enterprise Value Multiple | -5.47 | -11.63 | -86.13 | -30.10 | -48.76 |
| Enterprise Value | 33.91M | 56.86M | 58.31M | 167.24M | 146.83M |
| EV to EBITDA | -5.47 | -11.63 | -86.13 | -30.10 | -48.76 |
| EV to Sales | 4.09 | 142.85 | 12.37 | 25812.55 | 11409.60 |
| EV to Free Cash Flow | -5.17 | -15.89 | -197.81 | -51.34 | -60.88 |
| EV to Operating Cash Flow | -6.70 | -15.89 | -197.81 | -51.34 | -60.88 |
| Tangible Book Value Per Share | 0.02 | 0.03 | 0.11 | 0.11 | 0.19 |
| Shareholders’ Equity Per Share | 0.02 | 0.04 | 0.11 | 0.11 | 0.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.15 | 0.01 | 0.09 | 0.00 | 0.00 |
| Net Income Per Share | -0.13 | -0.09 | -0.01 | -0.11 | -0.07 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.16 | 1.00 | 1.00 | 1.00 | 1.02 |
| Research & Development to Revenue | 0.06 | 1.94 | 0.18 | 73.45 | 35.62 |
| SG&A to Revenue | 0.74 | 9.60 | 0.66 | 697.47 | 155.23 |
| Stock-Based Compensation to Revenue | 0.17 | 3.70 | 0.29 | 261.54 | 21.04 |
| Income Quality | 0.70 | 0.73 | 0.44 | 0.59 | 0.79 |
Currency in CAD
